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Abstract
Prostate cancers of luminal adenocarcinoma histology display a range of clinical behaviors. Although most prostate cancers
are slow-growing and indolent, a proportion is aggressive, developing metastasis and resistance to androgen deprivation
treatment. One hypothesis is that a portion of aggressive cancers initiate from stem-like, androgen-independent tumor-
propagating cells. Here we demonstrate the in vitro creation of a mouse cell line, selected for growth as self-renewing stem/
progenitor cells, which manifests many in vivo properties of aggressive prostate cancer. Normal mouse prostate epithelium
containing floxed Pten and TP53 alleles was subjected to CRE-mediated deletion in vitro followed by serial propagation as
protospheres. A polyclonal cell line was established from dissociated protospheres and subsequently a clonal daughter line
was derived. Both lines demonstrate a mature luminal phenotype in vitro. The established lines contain a stable minor
population of progenitor cells with protosphere-forming ability and multi-lineage differentiation capacity. Both lines formed
orthotopic adenocarcinoma tumors with metastatic potential to lung. Intracardiac inoculation resulted in brain and lung
metastasis, while intra-tibial injection induced osteoblastic bone formation, recapitulating the bone metastatic phenotype
of human prostate cancer. The cells showed androgen receptor dependent growth in vitro. Importantly, in vivo, the
deprivation of androgens from established orthotopic tumors resulted in tumor regression and eventually castration-
resistant growth. These data suggest that transformed prostate progenitor cells preferentially differentiate toward luminal
cells and recapitulate many characteristics of the human disease.
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Introduction
Prostate cancers (PC) display a range of clinical behavior; most
are relatively slow-growing tumors of minor clinical significance,
while about 10% develop to aggressive disease with poor prognosis
[1]. Human prostate adenocarcinoma has a mature luminal
phenotype distinguished by androgen receptor (AR) expression
and androgen-dependent survival. Progressive PC is characterized
by the ability to grow in androgen deprived conditions and to
metastasize, primarily to the bone, resulting in osteoblastic lesions
[2]. Understanding the biology of aggressive disease and the cellular
origins of castrate-resistant PC is a major goal of PC research.
The cancer stem cell (CSC) model posits a hierarchical
organization of tumors, with self-renewing stem-like cells that
generate progeny, which subsequently undergo epigenetically
programmed differentiation and loss of tumorigenicity [3,4,5].
The applicability of the CSC model for human prostate cancer is
not known. However, the presence of stem-like cells in human
prostate cancer xenografts and cell lines as well as in mouse models
has suggested that prostate cancer may contain epithelial popula-
tions with different extents of lineage commitment [6,7,8,9,10].
Another consideration with respect to prostate cancer pheno-
types is the potential cancer cells-of-origin. As has been shown for
breast cancer, the differentiation stage of the progenitor cell of
origin significantly influences the histological subtype of tumors
and their clinical behavior [11,12,13]. It has been implied, by two
different studies, that both basal and luminal progenitors can give
rise to adenocarcinoma and therefore act as the prospective cell of
origin for PC [14,15], although the lineage relationship of the two
target progenitor cells is not entirely clear. The lack of specific cell-
surface lineage markers for prostate epithelium has limited the
ability to define the number and relationship of prostate
progenitors and to obtain their significant enrichment.
The majority of prostate cancers have the appearance of
transformed luminal cells. We hypothesize that the prostate cancer
cell of origin will affect the lineage composition of minor tumor cell
populations and consequently the selective mechanisms contrib-
uting to the aggressive phenotype and the acquisition of castrate-
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26112resistance. Although multiple mechanisms appear to contribute to
castrate-resistant prostate cancer (CRPC), it has been hypothe-
sized that one origin might be immature, AR negative, tumor-
propagating cells, similar to multipotent progenitors [16,17,18].
The transformation of cells closer to the stem cell apex in lineage
hierarchy might be expected to increase the likelihood of
immature progenitor cells in tumors.
Underlying mutations are known to be major determinants in
the clinical behavior of tumors. Loss of PTEN and aberrations of
TP53 are implicated in aggressive forms of human PC. One of the
most common alterations in prostate cancer, which occurs in
.70% of human prostate cancers, is loss of expression of the
PTEN tumor suppressor, and biallelic deletion of PTEN is
correlated with CRPC [19]. Although alterations to TP53
previously have been thought to be exclusively associated with
advanced disease, a recent genomic profiling study of mostly
primary prostate cancers demonstrated that 24% of cases had
either a hetero- or homozygous copy number loss of TP53 [20].
Consistent with abnormal TP53 contributing to PC progression,
other large scale studies using combined immunohistochemistry
and sequencing approaches have shown that TP53 mutations
occur in approximately 5% of primary tumors and at much higher
frequencies in lymph node metastases (16%) and castrate-resistant
(26%) tumors [21,22]. Additionally, TP53 mutations were found
to be independent predictors of tumor recurrence in low and
intermediate grade cancers.
Modeling prostate cancer in the mouse has shown that prostate
epithelial cell-specific loss of Pten and TP53 results in aggressive,
lethal disease that is significantly more penetrant and rapidly
developing than prostate cancer resulting from Pten deletion alone
[23,24]. In vitro assays of progenitor self-renewal as measured by
serial propagation of protospheres demonstrated greatly increased
self-renewal activity in Pten/TP53 null relative to wild type prostate
epithelium [25]. Adenocarcinoma is the main initial tumortype that
arises in the prostate epithelial Pten/TP53 null model. Further-
more, adenocarcinoma tumors were observed most often upon
orthotopic transplantation of Pten/TP53 null protospheres [25].
In order to originate a model of progenitor-driven prostate
cancer, we initiated deletion of tumor suppressor genes in vitro in a
functionally-defined progenitor population, namely protospheres.
Following additional serial protosphere propagations, cell cultures
were established. Here we characterize a cell line and its clonal
derivative arising from such an approach. Both cell lines display
AR
+ luminal phenotypes while maintaining evidence of a
progenitor population. Of interest, without prior in vivo selection,
these lines express many properties of aggressive prostate cancer
including metastatic ability, the generation of an osteoblastic
response upon growth in bone, and the potential for castrate-
resistant growth.
Results
Isolation and characterization of prostatic epithelial cell
lines from the Pten/TP53 conditional knock-out model
To determine the characteristics of prostate epithelial progenitor
cell lines with genomic loss of Pten and TP53 we made use of a
tamoxifen inducible Cre murine model containing floxed Pten and
TP53 alleles(Fig.1).Single cellsuspensions ofprimary prostaticcells
isolated fromintactRosa26-Cre
ERPten
fl/flP53
fl/fl micewere suspended
in Matrigel
TM together with serum-free minimal media and tamox-
ifen. The protospheres that formed were serially passaged for three
generations to further enrich for stem/progenitor cells with self-
renewal activity. Subsequently, the protospheres were dissociated
and cells were cultured as monolayers in the presence of 2.5% FBS.
After establishing a monolayer culture, cells were weaned off serum
until they grew in serum-free media, where no exogenous androgen
was added to the growth media. The polyclonal parental cells,
PLum-P, were used to generate daughter clones derived from single
cells. The clonal line, PLum-C, was selected for further analysis
based upon demonstrating the ability to form protospheres.
A quantitative reverse transcription-PCR (QRT-PCR) and
Western Blot (WB) analyses were performed to characterize the
genotype of the cells. QRT-PCR and WB data confirmed the
deletion of Pten and TP53 in both PLum-P and PLum-C cell lines
(Fig. 2A and 2B). To determine the cellular phenotype of these
established cell lines, microscopic analyses using markers for the
major cell types in the prostate epithelium were performed. PLum-
P and PLum-C cells showed typical epithelial cell morphology
with a cobble-stone appearance and well-defined cell boundaries
(Fig. 2C). PLum-P and PLum-C cells were stained for lineage
markers including CK5 and CK14, CK8, and b3 tubulin, which
are characteristically expressed in basal, luminal and neuroendo-
crine cells, respectively. While all the cells expressed CK8, CK5
was not detected and minor populations of cells co-expressed
CK14 and CK8 (less than 5%) and Vimentin and CK8 (less than
1%) (Fig. 2D). Furthermore, very rare neuroendocrine (b3 tubulin
+ve) cells were detected. In addition to CK8, both cell lines
expressed heterogenous levels of AR and the prostate luminal
epithelial marker NKX3.1, suggesting the existence of mature and
immature CK8
+ cells (Fig. 2D). Moreover, WB analysis showed
the expression of AR, CK8, NKX3.1 and E-cadherin in both
Plum-P and Plum-C cells (Fig. 2E). Given the clonal nature of the
PLum-C line, these data show that a predominantly luminal
epithelial phenotyped cell line has retained capacity to produce
cells expressing basal and neuroendocrine markers, and imply that
immature cells with differentiative ability exist within the culture.
PLum-P and PLum-C sphere-forming cells retain
self-renewal ability and differentiation plasticity in vitro
To determine whether the cell lines have stem/progenitor cell-
like properties, including self-renewal ability and differentiation
Figure 1. Isolation of Pten
-/-TP53
-/- cell lines from Pten-/-TP53-/-
prostate spheres. An illustration of the generation of prostate
epithelial cell lines. Cells were subcloned and the parental cells are
referred to as PLum-P (Prostate Luminal-Parental) and the clone as
PLum-C (Prostate Luminal-Clone).
doi:10.1371/journal.pone.0026112.g001
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select for the growth of prostate epithelial stem/progenitor cells in
vitro. In addition to forming protospheres in an anchorage-
independent manner (absence of Matrigel
TM), both cell lines
formed protospheres at comparable efficiency (8% for PLum-P
and 10.6% for PLum-C) when suspended in serum free media in
the presence of a semi-solid basement membrane-Matrigel
TM,
suggesting the existence of cell populations expressing stem/
progenitor characteristics (Fig. 3A and 3B). Furthermore, both
PLum-P and PLum-C cells serially propagated as protospheres
without losing sphere forming capacity, indicating stable self-
renewal ability (Fig. 3B). To assess differentiation potential, PLum-
P and PLum-C protospheres were stained for lineage markers
including CK5, CK8, CK14, and b3 tubulin. Confocal images
through PLum-P and PLum-C protospheres costained for CK5/
CK8, CK14/CK8 or b3 tubulin/CK8 are shown in Figure 3C.
Interestingly, while no CK5 was detected in monolayer cultures,
approximately 20–25% of PLum-P and PLum-C protospheres
contained cells demonstrating CK5, CK8, and CK5
+/CK8
+
expression. Furthermore, almost 75% of PLum-P and PLum-C
protospheres contained cells expressing CK14, CK8, and CK14
+/
CK8
+. Moreover, b3 tubulin positive cells were detected in
occasional protospheres. These data suggest that the microenvi-
ronment provided by Matrigel
TM induces differentiation toward
the basal lineage that is rarely observed in monolayer culture and
demonstrates that protosphere-forming cells have maintained
multipotent differentiation plasticity.
PLum-P and PLum-C cells form adenocarcinoma in vivo
containing the three prostate epithelial cell lineages
We subsequently examined the tumorigenic potential of PLum-
P and PLum-C cells. Both PLum-P and PLum-C rapidly formed
tumors upon subcutaneous transplantation in male nu/nu mice
and the major histological type of tumor detected was
adenocarcinoma with areas of poorly differentiated or sarcoma-
toid carcinoma (Fig. S1). The tumor phenotype was further
characterized following orthotopic growth in male nu/nu mice
receiving androgen supplements. The majority of tumor area
formed by PLum-C orthotopic transplantation was comprised of
adenocarcinoma with minor compartments of poorly differenti-
ated or sarcomatoid carcinoma (Fig. 4A and Table 1). Immuno-
histological examination of serial orthotopic tumor sections was
performed. PLum-C orthotopic adenocarcinoma was comprised
of cells with a luminal (CK8
+/CK14
-/CK5
-) and/or intermediate
(CK8
+/CK14
+/CK5
+/-) phenotype (Fig. 4A and Table 1).
Moreover, rare cells with basal phenotype (TP63 or CK5 or
CK14 only) were also detected. Orthotopic adenocarcinoma
uniformly displayed strong nuclear labeling of AR. Cells
expressing the neuroendocrine lineage marker synaptophysin
were also present throughout the tumors and were positive for p-
AKT indicating their tumorigenic origin (Fig. S2). Overall,
PLum-C orthotopic adenocarcinoma tumors displayed a glandu-
lar luminal phenotype with relatively frequent occurrences of
CK8/Synaptophysin double positive cells and rare occurrences of
basal cells. Similarly to the various lineage markers observed in
vitro, the tumor data suggest that PLum-P and PLum-C cell lines
demonstrate differentiation plasticity.
PLum-P and PLum-C cells have metastatic potential and
induce osteoblastic bone tumor formation
The metastatic potential of the cells was investigated next.
Despite no prior in vivo selection for tumorigenic growth, small
undifferentiated lung metastases were observed in 3/8 mice with
PLum-C orthotopic adenocarcinoma (Fig. 4B). These microme-
tastases were comprised of luminal (CK8) cells with varying
percentages of intermediate cells (CK8
+/CK14
+). While synapto-
Figure 2. Lineage characterizations of Pten
-/-TP53
-/- cell lines. (A) Pten and TP53 expression was determined using QRT-PCR analysis and values
were normalized to Actin.( B) PTEN and TP53 expression was determined using WB analysis. (C) Representative bright field images of PLum-P and
PLum-C cells. Scale bar =100 mm. (D) Representative immunofluorescent images of PLum-P and PLum-C cells stained for the indicated antibodies
and Dapi are shown. Scale bars =20 mm. (E) WB analysis for the indicated proteins in Plum-P and Plum-C cells is shown.
doi:10.1371/journal.pone.0026112.g002
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detected, TP63 and nuclear AR were not observed. These data
suggest that the cells with the greatest metastatic capacity are
immature luminal-lineage cells. In addition to orthotopic trans-
plantation, an experimental metastasis assay was performed using
intracardiac left ventricle inoculation. PLum-P and PLum-C cells
carrying a luciferase reporter were used in order to monitor the
growth over time using bioluminescent imaging. Brain metastases
(12.5% frequency) were detected after three months in mice
inoculated with PLum-P and PLum-C cells (Fig. 5A). Lung
metastases were also detected at the same frequency. Immunohis-
tological analysis of brain serial sections showed that the
metastases were positive for CK8 and CK8
+/CK14
+ staining,
indicating their epithelial origin. As in the case with lung
metastasis from orthotopic tumors, brain metastases showed rare
CK5 but no TP63 or nuclear AR expression.
A major clinical challenge in prostate cancer comes from the
propensity of the progressive disease to metastasize to bone,
leading to significant morbidity and eventually death. Prostate
cancer bone metastasis displays characteristic osteoblastic, rather
than osteolytic, lesions. To determine whether the cells produce
tumors in the bone microenvironment, PLum-C cells were
injected intratibially into male nu/nu mice. Using x-ray imaging,
osteoblastic lesions were detected, as early as eight weeks post
injection, in 50% of inoculated mice. Histological analysis was
used to confirm the presence of osteoblastic lesions induced by
PLum-C cells, and serial sections were stained for CK8 to show
the epithelial origin of the cells (Fig. 5B).
In vitro androgen dependence and the development of
castrate resistance in vivo
Because androgen-dependance is a typical characteristic of
prostate adenocarcinoma, we sought to determine the behavior of
cells under conditions of inhibited androgen receptor (AR)
signaling. PLum-C cells (1610
4) were grown in serum-free
prostate media in the presence of increasing concentrations of
Bicalutamide, an AR antagonist, and 1 mM and 10 mM Bicalu-
tamide resulted in 20% and 70% inhibition of growth, respectively
(Fig. 6A). This suggests that AR function is required for sustaining
in vitro cell proliferation in the majority of cells, even though
exogenous androgen was not supplied. Subsequently, we investi-
gated whether androgen ablation in vivo would delay morbidity
from tumor burden as seen in clinical cases. Single cell suspensions
of PLum-C cells were injected orthotopically into the prostates of
castrated male nu/nu mice in the presence of an implanted
testosterone pellet, and growth was monitored over time using
bioluminescent imaging. Six weeks post injection, mice were
randomly divided into two cohorts. Androgen pellets were
removed from one group and replenished in the other group.
The survival of mice with androgen supplementation ranged from
6 to 10 weeks. Animals switched to androgen deprivation
conditions showed increased survival, ranging from 13 to 17
Figure 3. Pten
-/-TP53
-/- cell lines displaying stem-like cell properties. (A) Representative bright field images of PLum-P and PLum-C
protospheres in Matrigel
TM (upper panel) and in suspension (lower panel) are shown. Scale bar =100 mm. (B) PLum-P and PLum-C cells were plated
in Matrigel
TM at a density of 2,000 cells/well for sphere formation assay. Sphere forming units expressed as % of 2,000 input cells at each generation
obtained from serially passaged protospheres are shown. The data are reported as mean 6 SD. (C) immunofluorescent images of confocal cross
sections from representative PLum-P and PLum-C protospheres stained for CK5, CK8, CK14, b3 tubulin and Dapi. Scale bar =50 mm.
doi:10.1371/journal.pone.0026112.g003
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luminal epithelial differentiation. (A) Orthotopic tumors were generated by injecting PLum-C cells in surgically castrated nude male mice with
implanted testosterone pellet. Serial sections of orthotopic tumors were stained with H&E, AR, CK5, CK14, CK8, Synaptophysin, TP63, and Dapi. Scale
bar =10 mm. (B) Representative sections of lung metastasis from orthotopic injection of PLum-C cells stained with H&E, CK8, CK14, and Dapi. Scale
bar =10 mm, unless otherwise stated. Sections for immunofluorescent staining were cut at least 50 mm deeper relative to the first H&E section. Red
arrowheads indicate lung metastasis, and white asterix indicate lung epithelium.
doi:10.1371/journal.pone.0026112.g004
Table 1. Summary of immunohistochemical marker expression in PLum-C orthotopically transplanted tumors with and without
androgen.
Androgen replete Androgen deplete
IHC Marker Adeno (Major) Sarc (Minor) Adeno (Minor) Sarc (Major)
CK8 +++ ++Q +++ ++Q
CK5 ++ - ++ -
CK8+/CK5+ ++ - ++ -
CK14 ++ ++ ++ +
CK8+/CK14+ ++ ++ ++ +
TP63 + - + -
AR ++ ++Q +/-Q +/-Q
Synaptophysin ++ ++ ++ ++
Vimentin +/- +++ +/- +++
Vimentin/CK8+ +/- ++ +/- ++
Lung Metastases 3/8 3/6
Adenocarcinoma (Adeno.), sarcomatoid carcinoma (Sarc.). +++ marker present in most or all cells (80%–100%), ++ marker present in many cells (50%–80%), however
there are significant numbers of cells that lack expression, + marker present in a minority of cells (5%–50%), +/- marker is present in only rare populations of cells (less
than or equal to 5%), - absence of marker. qDenotes increased and Qdenotes decreased IHC labeling intensity relative to epithelial cells in adjacent normal prostate.
All lung metastasis were CK8
+ with variable levels of CK14 expression. CK5 and Vimentin expression was rarely detected, and TP63 and AR expression was not detected.
doi:10.1371/journal.pone.0026112.t001
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supplemented orthotopic prostate tumors were comprised mainly
of adenocarcinoma with minor components of solid/undifferen-
tiated and sarcomatoid carcinoma (Fig. 4A, Fig. 6C and Table 1).
This histological appearance was reversed in androgen-deprived
orthotopic tumors, which were comprised of primarily sarcoma-
toid carcinoma (approximately 50–75% estimated tumor area),
with the rest being solid/undifferentiated and less than approx-
imately 10% adenocarcinoma (Fig. 6C). Regardless of the androgen
status, all orthotopic tumors were highly invasive into the adjacent
normal recipient prostate gland and stroma, and lymphovascular
invasion was common. As in the adenocarcinoma, sarcomatoid
carcinoma was also comprised of cells with a luminal (CK8
+/
CK14
-/CK5
-) or intermediate phenotype (CK8
+/CK14
+/CK5
-),
with the notable exception of the absence of CK8
+/CK14
+/CK5
+
cells (Table 1). Sarcomatoid carcinomas demonstrated epithelial to
mesenchymal transition as the cells displayed reduced CK8
expression (with occasional foci of CK8 loss) coupled with nearly
ubiquitous vimentin co-expression. Synaptophysin expression was
observed diffusely in a proportion of cells throughout all tumors
regardless of histological pattern or androgen status. Thus,
androgen deprivation selected for the growth of poorly differenti-
ated cells co-expressing luminal, mesenchymal and neuroendocrine
lineage markers. AR expression was strongly influenced by the
androgen status of the recipient mouse. Orthotopic tumors in
androgen-supplemented mice displayed strong nuclear labeling in
adenocarcinoma with almost complete loss of nuclear labeling in
sarcomatoid carcinoma. In both patterns there were occasional foci
with loss of nuclear AR. Androgen deprivation led to almost
complete loss of nuclear AR in all tumors, with only rare foci
containing low cytoplasmic expression. As in the androgen-replete
tumors, smallundifferentiated lung metastaseswereobserved in3/6
androgen-deprived mice, with no notable differences in the
differentiation markers when compared to lung metastases from
androgen-replete and depleted metastases.
Discussion
We describe here the in vitro origination from protospheres of a
prostate epithelial cell line and clonal derivative that give rise to
adenocarcinoma tumors and display properties of progressive
prostate cancer, including metastatic potential and castrate-
resistant growth. Here, we have directly established a cell line
from progeny resulting from the initiation of Pten/TP53 tumor
suppressor loss in prostate epithelial stem/progenitor cells. In stem
cells, TP53 controls the generation of self-renewing daughter stem
cells and suppresses pluripotency [25]. PTEN negatively regulates
cell cycle entry via AKT-dependent and AKT-independent
pathways [26,27,28]. The combined loss of Pten and TP53 results
in robust prostate progenitor amplification, consistent with rapid
and heterogeneous tumor development in the Pb-Cre4;Pten
fl/fl;
TP53
fl/fl mouse model [24,25].
Figure 5. Pten
-/-TP53
-/- cells metastasize to brain following intracardiac injection and induce osteoblastic bone tumor formation
upon intratibial injection. (A) Brain metastases were generated by intracardiac injection of PLum-P and PLum-C cells into nude male mice. Cross
sections of brain tissues stained with H&E and labeled with antibodies against CK8, CK14, and Dapi showing metastases. Scale bar =10 mm. Sections
for immunofluorescent staining were cut at least 50 mm deeper relative to the first H&E section. (B) Osteoblastic lesions were detected upon
intratibial injection of PLum-C cells into nude male mice. Cross sections of osteoblastic tibia bones stained with H&E/Orange G and CK8. Scale bar
=100 mm. A magnified tumor focus as indicated by a boxed area in the middle panel is shown on the right. Scale bar =20 mm.
doi:10.1371/journal.pone.0026112.g005
Protosphere-Derived Metastatic Adenocarcinoma Cells
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26112The PLum-P/C lines grown in vitro have a CK8
+/CK5
-/
NKX3.1
+/AR
+ luminal epithelial phenotype. Importantly, a
population of cells has retained multipotency and/or differentiative
plasticity. This is demonstrated in clonally-initiated protospheres by
the presence of multiple cell types displaying various differentiation
markers including intermediate cytokeratin phenotypes, CK8
+/
CK5
+andCK8
+/CK14
+,andbyb3-tubulin/CK8
+ cells.Similarly,
we observed in PLum-P/C tumors, cell populations displaying
intermediate cytokeratin profiles, neuroendocrine markers, and
occasionally the definitive basal marker, TP63. These results
parallel the expectations for multipotent self-renewing progenitor
cells that mainly differentiate to luminal cells, suggesting that the
PLum model will be useful to investigate the cancer stem cell model
of prostate cancer. To date there is limited knowledge concerning
the differentiation status and correlative tumorigenic and metastatic
properties of prostate cancer tumor initiating cells [5,16]. In one
recently described model, cell fractionation studies of CWR22
human prostate cancer xenograft tumors demonstrated that tumor
protospheres containing CK8
+/CK5
+/AR
-/TP63
- cells gave rise to
CK8
+/CK5
-/AR
+ tumors [10]. Taken together, these data support
the hypothesis that immature progenitor cells give rise to
adenocarcinoma.
PLum-P/C tumors recapitulate many properties of human PC,
i.e. clinical progressive adenocarcinoma. The capacity of PLum
cells to metastasize from an orthotopic tumor or following
intracardiac inoculation is relatively rare among prostate cancer
cell lines. Interestingly, metastatic colonization appeared to initiate
from progenitor cells with differentiation capability since both
CK8
+/CK14
+ and CK8
+/CK14
- cells were observed in individual
metastases. The lack of AR in metastases also suggests a relatively
immature metastasis-initiating cell. In addition, following intra-
tibial inoculation, PLum-C cells formed tumors that elicited an
osteoblastic response, characteristic of clinical prostate cancer
metastasis [1,2]. Bone is the most common site of prostate cancer
metastasis, and therefore understanding the molecular mecha-
nisms that promote prostate cancer metastasis to bone is a priority.
Most existing prostate cancer intratibial models lead to osteolytic
metastases, which has limited the ability to investigate the
interaction of PC cells with the bone microenvironment to elicit
osteoblastic responses [29].
PLum-C tumors regressed in response to androgen deprivation,
consistent with an AR
+ luminal phenotype for the majority of
tumor cells. We observed subsequently arising castration-resistant
tumors that had significantly decreased AR levels and had
undergone an EMT to produce tumors containing many CK8
+/
Vimentin
+ cells. It is not clear whether AR signaling has an active
role in suppressing EMT, or alternatively, spontaneously-arising
sarcomatoid cells may selectively survive androgen deprivation.
In conclusion, here we demonstrate the establishment of a cell
line from a pre-enriched source of progenitor cells containing
Figure 6. In vitro androgen dependence and in vivo castrate resistance of PLum-C cells. (A) Effect of Bicalutamide on the proliferation of
PLum-C cells. PLum-C cells were incubated with the indicated concentrations of Bicalutamide or DMSO vehicle for six days in serum free PrEGM. The
number of viable cells was determined by trypan blue exclusion. The data are reported as mean 6 SD (*, p,0.05). (B) Orthotopic tumors were
generated by injecting PLum-C cells in surgically castrated nude male mice with implanted testosterone pellet. At week six post injection, mice were
randomly separated into two groups and testosterone pellets were either removed (androgen deplete) or replenished (androgen replete) in each
group. Mice were sacrificed upon showing signs of morbidity and the survival rate was plotted. (C) Serial sections of orthotopic tumors were stained
with H&E, AR, Vimentin, CK8, CK14, and Dapi. Scale bar =20 mm.
doi:10.1371/journal.pone.0026112.g006
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progressive human prostate cancer. These cell lines recapitulate
the many aspects of the human disease, namely the formation of
metastatic adenocarcinoma. While other prostate cancer cell lines
have been established both from primary tumors and from
metastases, to our knowledge this is the first prostate cancer cell
line to utilize such an approach. This approach allows for a more
detailed understanding of the potential contribution of progenitor
cells to properties of progressive prostate cancer, and this model
adds to the resources available to investigate the molecular
mechanisms contributing to prostate tumor progression and
metastasis. For example, models to test therapeutic approaches to
treat osteoblasticbonemetastasisareanareaofcurrentunmetneed.
Materials and Methods
Ethics Statement
All animal experiments were done according to the protocol
(LCB-018) approved by the National Cancer Institute Guideline
for Use and Care of Animals.
Cell Culture
Reagents. PrEGM with supplements was from Lonza
(Lonza, MD), and DMEM containing 10% FBS and antibiotic
reagents were purchased from Invitrogen (Invitrogen, CA).
Dispase, collagenase type II and trypsin were purchased from
Invitrogen. BD Matrigel
TM was purchased from BD Biosciences
(BD Biosciences, CA). Bicalutamide was from Sigma-Aldrich
(Saint Louis, MO).
Preparation of Primary Mouse Prostate Epithelial
Cells. Three to five month old Rosa26-Cre
ERPten
fl/flP53
fl/fl mice
were euthanized by carbon dioxide inhalation and the entire lower
urogenital tract aseptically removed and placed in 35-mm Petri
dishes in prostate harvest media (DMEM containing 10% FBS, 1%
penicillin/streptomycin,gentamicin(300 mg/ml),and amphotericin
B (0.5 mg/ml). All prostate lobes were micro-dissected away from
the remaining urogenital tract tissues, pooled and placed in 35-mm
Petri dishes in prostate dissection media (prostate harvest media
with collagenase type II at 1 mg/ml). Prostatic tissue was finely
minced using a sterile scalpel blade, collected, and incubated in
prostate dissection media on a spinning wheel for 1 hr at 37uC.
Tissue suspensions were centrifuged for 6 min at 1000 rpm, and the
pellet (organoids) was resuspended in at least 0.5 ml of 0.05%
trypsin-EDTA and incubated for 5 min at 37uC. The organoid/
trypsin suspension was carefully passed through 19, 23, 25, 27.5,
and 31 gauge needles before the trypsin was neutralized using
prostate harvest media. To confirm that a single cell suspension was
achieved, an aliquot ofthe cell suspensionwas placedona glassslide
and the integrity and separation of cells was examined under a
microscope. The cell suspension was centrifuged for 6 min at 1000
rpm and washed once with serum free prostate epithelial cell basal
media,PrEGM(supplementedasdirected bythemanufacturerwith
bovine pituitary extract, insulin, hydrocortisone, gentamicin, am-
photericin B, retinoic acid, transferrin, T3, epinephrine, recombi-
nant human epidermal growth factor, and penicillin/streptomycin).
After washing, cells were passed through a 40 mm cell strainer and
centrifuged for 6 min at 1000 rpm. Finally, the pellet was
resuspended in 1 ml of PrEGM and the number of viable cells
was counted using the trypan blue exclusion method.
Establishment of de novo Pten
-/-/TP53
-/- mouse prostate
epithelial cell lines
3-D Cultures and Sphere-formation Assay. Single cells
were suspended in Matrigel
TM/serum free PrEGM (1:1) at a
concentration of 10,000 cells/well in a total volume of 100 ml, in
triplicate. The solution was plated gently around the rim of
individual wells of a 12-well plate and allowed to solidify for 1 hr
at 37uC in a humidified incubator. Tamoxifen-containing serum
free PrEGM was added gently to the center of each well and the
media was changed every two to three days. Spheres were
harvested between days 12 and 15 after plating.
Propagation of spheres. Media was gently aspirated from
the center of the well, and the Matrigel
TM was digested by
incubation in 500 ml of serum free PrEGM containing dispase
(1 mg/ml) for 1 hr at 37uC in a humidified incubator. The
resulting sphere containing solution was collected and centrifuged
at 1000 rpm for 6 min. The resulting pellet was resuspended in
500 ml of serum free PrEGM containing collagenase II (1 mg/ml)
and incubated for 1 hr on a spinning wheel at 37uC. The
suspension was centrifuged at 1000 rpm for 6 min and was
resuspended in 500 ml of 0.05% trypsin-EDTA. The solution was
directly passed through a series of needles (21, 25, 27 and 31
gauge). Trypsin was inactivated by adding PrEGM media
containing 5% FBS, and cells were centrifuged at 1000 rpm for
6 min, washed once and resuspended in serum free PrEGM. The
number of viable cells was determined using the trypan blue
exclusion method. Cells were then resuspended in Matrigel
TM and
plated as described before (10,000 cells/well). Spheres were
propagated for three generations and enriched progenitor cells
were then switched to 2-D cultures.
2-D Cultures. Single cell suspensions obtained from
Generation 3 spheres as described above were seeded in 6-well
plates in PrEGM containing 2.5% FBS at a density of 20,000
cells/well in triplicate and incubated at 37uC in a humidified
incubator. After a monolayer of epithelial cells was formed, cells
were trypsinized, counted and plated as before. After growing in
PrEGM containing 2.5% FBS for 5 passages, the serum
concentration was gradually decreased to 0.5 and then to 0.
Cells with CK5
+/CK8
+ expression were detected in early passages
and while in serum. No CK5 expression was detected once cells
were transferred to serum-free media. All the experiments shown
were carried out with cells grown in serum free PrEGM. Plum-P
(Prostate Luminal-Parental) refers to the parental cell line and
Plum-C (Prostate Luminal-Clone) refers to a clonal daughter cell
line generated from Plum-P cells.
Immunofluorescence and Confocal Microscopy
Antibodies and Reagents. Antibodies from the indicated
manufacturers used in this study were as follows: mouse
monoclonal anti-CK8, rabbit polyclonal anti-CK14, and rabbit
polyclonal anti-CK5 (Covance, CA), rabbit polyclonal anti-b3
tubulin (Millipore, CA), rabbit polyclonal anti-synaptophysin and
rabbit polyclonal anti-NKX3.1 (Abcam, MA), rabbit polyclonal
anti-AR (Santa Cruz Biotechnology, CA), Alexa 488 goat anti-
mouse, goat anti-rabbit, Alexa 568 goat anti-mouse, goat anti-
rabbit (Invitrogen, CA). Fluoro-gel II with Dadi was purchased
from EMS (Electron Microscopy Sciences, PA).
Staining Procedures for monolayer cells. Adherent cells
were fixed in 4% paraformaldehyde (PFA) in PBS for 10 min,
followed by permeabilization with 0.5% Triton X-100 in PBS for
2 min. Non-specific sites were blocked by incubation in 2% BSA
in PBS for 30 min. Cells were then incubated overnight at 4uC
with the specified antibodies in 2% BSA/PBS. Cells were washed
three times with PBS containing 0.1% Tween-20, incubated with
Alexa-488 and/or 568 conjugated IgG in 2% BSA for 30 min at
room temperature, and finally washed and mounted using the
anti-fade reagent Fluoro-gel II with DAPI. Fluorescent signals and
bright field images were captured using an inverted upright
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Mk4 confocal microscope.
Staining Procedures for Protospheres. Cells were grown
in 35 mm glass bottom culture plates with 10 mm microwell
(MatTek Cultureware, MA) in Matrigel
TM-containing media as
described above. Spheres were fixed in-situ in 4% PFA at room
temperature for 20 min. The PFA was aspirated gently and
spheres were permeabilized with 0.5% Triton X-100 for 30 min at
room temperature. After carefully aspirating the permeabilization
solution, spheres were blocked using the sphere blocking buffer
(0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20, and 10%
normal goat serum in PBS) for 2 hrs at room temperature. Spheres
were incubated overnight with primary antibodies at 4uC. After
gentle washing with PBS containing 0.1% Tween-20, spheres were
incubated with Alexa-488 and/or 568 conjugated IgG for 2 hrs at
room temperature. The culture plates were then washed gently,
and 50 ml of the anti-fade reagent Fluoro-gel II with DAPI was
added directly on the microwell and a 12-mm glass coverslip was
gently mounted. Confocal microscopic analyses were performed
using Zeiss LSM 510 Meta Mk4 confocal microscope and images
were acquired and analysed using the Zeiss LSM image software.
Histology and Immunohistochemistry
Subcutaneous tumors and brain and lung tissues were harvested
and fixed in 4% PFA overnight, rinsed well in PBS, and
transferred to 70% ethanol before standard processing to obtain
paraffin-embedded sections. Unstained tissue sections were
deparaffinized, and antigen retrieval was performed in a citrate
buffer (DAKO targeted antigen retrieval solution) in a steamer at
100uC for 15 min followed by 15 min incubation at room
temperature. Blocking was performed with Cyto Q Background
Buster reagent (Innovex Biosciences, Richmond, CA) for 30 min
at room temperature. Primary antibody incubation was performed
overnight at 4uC, followed by secondary antibody incubation at
room temperature for 30 min. The ABC peroxidase kit (Vector
Laboratories, Burlingame, CA) was used followed by DAB (Dako,
Carpinteria, CA) for chromogen visualization. All slides were
counterstained with hematoxylin.
In Vivo Transplantation
Subcutaneous Transplantation. A total of 1610
6 PLum-P
or PLum-C cells in 50 ml was mixed 1:1 with growth factor
reduced Matrigel
TM (Becton Dickinson) immediately prior to
injection. Cells were injected subcutaneously into the flanks of 8–
10 week old BALB/c nu/nu male mice. Mice were euthanized
upon signs of morbidity.
Orthotopic Transplantation. 8–10 week old BALB/c nu/nu
male mice were anesthetized and a midline skin incision was
made. Mice were surgically castrated prior to cell inoculation.
PLum-C cell suspensions (500,000 cells in 10 ml prostate harvest
media) were injected using a 30-gauge needle, a 50 ml Hamilton
syringe, and a surgical micromanipulator with a microsyringe
pump (World Precision Instruments) into one of the anterior
prostatic lobes by gently retracting the bladder and seminal
vesicles caudally with a sterile moist cotton swab. Standard
surgical procedures were used to repair the abdominal
musculature and incision. Testosterone pellets (5 mg) were
surgically implanted subcutaneously intrascapular at the time of
castration. All procedures of the operation described above were
performed under a bio-hood with a surgical microscope (World
Precision Instruments). Bioluminescent imaging was used biweekly
to monitor the growth of tumors and mice were euthanized when
they showed signs of morbidity.
Intracardiac Transplantation (Experimental Metastasis).
A total of 1610
5 PLum-P or PLum-C cells in 100 mlo fP B Sw e r e
inoculated into the left cardiac ventricle of male nude mice under
anesthesia. Bioluminescent imaging was determined bi-weekly to
monitor the development of metastasis. Mice were euthanized after
demonstrating signs of morbidity and tissues were collected and fixed
in 4% PFA for histological analysis (HistoServ, Inc.).
Intratibial Transplantation. Mice were anesthetized, the
knees were flexed to a 90u angle, and a 27-gauge needle was
inserted through the tibial plateau. A Hamilton syringe was used
to accurately inject 25 ml of PLum-C cells in PBS (1610
5) into the
proximal tibia. Radiography was determined bi-weekly using an
MX-20 Faxitron x-ray system (Faxitron) to monitor the growth of
tumor and sign of lesions in bone. Mice were euthanized when
bone lesions were detected upon X-ray examination. Tibial bones
were collected and fixed in 4% PFA for histological analysis.
In Vitro Proliferation Assay
PLum-C cells were seeded in triplicate in 6-well plates at a
density of 1610
4 cells per well. Cells were grown for six days in
serum-free PrEGM in the presence of DMSO or DHT (5 nM) or
Bicalutamide (1 mM and 10 mM). Cells were then trypsinized and
counted using trypan blue exclusion method.
Reverse Transcription-PCR
Total RNA was isolated from cells using the RNeasy Micro Kit
(Qiagen) according to the manufacturer’s instructions. cDNA was
generated from total RNA using the Super Script III First Strand
Synthesis System for RT-PCR (Invitrogen). PCR was performed
using Platinum Taq Polymerase (Invitrogen). SYBR Green
Mastermix was used for quantitative RT-PCR on the Stepone
Plus RT-PCR system (Applied Biosystems). All reactions were run
in triplicate using the primers listed below, designed on Genescript
or Primer 3. All values were normalized to Actin. The primers
used were: Actin-F: 59TCCTCCCTGGAGAAGAGCTA39; Ac-
tin-R: 59ACGGATGTCAACGTCACACT39. Pten-F:59TTGAA-
GACCATAACCCACCA39; R:59TTACACCAGTCCGTCCC-
TTT39. TP53-F:59TGGTGGTACCTTATGAGCCA39;R :5 9A-
GGTTCCCACTGGAGTCTTC39.
Data analysis
The significance of the data was analyzed using a Student’s t-
test, and differences between two means with a P,0.05 were
considered significant. Error bars represent the standard error of
the mean (SEM).
Supporting Information
Figure S1 Pten
-/-TP53
-/- cell lines form adenocarcinoma
in vivo and express various differentiation markers. (A)
Subcutaneous tumor was generated by injecting male nu/nu mice
with PLum-P and PLum-C cells. Cross sections of subcutaneous
tumors stained with H&E showing typical adenocarcinoma
generated by PLum-P (left panel) and PLum-C (right panel) cells
are shown. Scale bar =10 mm. (B) representative sections of
PLum-C subcutaneous tumor stained for CK5, CK8, CK14, AR,
TP63, Synaptophysin, and Dapi. Scale bar =10 mm.
(TIF)
Figure S2 The tumorigenic origin of Synaptophysin+
cells in Plum-C orthotopic tumors. A representative section
of Plum-C orthotopic tumors co-stained for Synaptophysin, P-
AKT, and Dapi. Scale bar =10 mm.
(TIF)
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